New treatment approach for mantle cell lymphoma
Official title: Developing novel therapy to improve outcomes in MCL
Funded at Ohio State University · NIH-10886820 · Data updated 2026-11-12
This study is looking at a new treatment for mantle cell lymphoma (MCL) that targets a specific protein to help kill cancer cells and hopefully improve outcomes for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | July 12, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $386,632 |
| NIH project number | 5R01CA282483-02 |
| Project ID | NIH-10886820 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with mantle cell lymphoma who have experienced relapse after standard treatments.
✕Less likely to help
Patients with other types of lymphoma or those who have not been diagnosed with mantle cell lymphoma may not benefit from this research.
What this research studies
This research focuses on developing a novel therapy for mantle cell lymphoma (MCL), a type of non-Hodgkin lymphoma that is currently incurable. The study investigates the role of Fibroblast Growth Factor Receptor-1 (FGFR1) in MCL survival and how it regulates cell cycle processes. By targeting FGFR1 with a specific drug, the research aims to induce cell death in cancer cells and improve patient outcomes. Patients may benefit from preclinical studies that explore the effectiveness of this targeted therapy.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and better treatment options for patients with relapsed mantle cell lymphoma.
How similar studies have gone: Previous research has shown promising results in targeting FGFR1 in other cancers, suggesting potential success for this novel approach in mantle cell lymphoma.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Sehgal, Lalit — Ohio State University
- Study coordinator: Sehgal, Lalit
Related research
Other NIH-funded projects on the same topics.
-
Understanding how trinucleotide repeat expansions cause disease
A research project at Ohio State University is exploring how tiny DNA repeats become unstable and drive neurological and muscular diseases, with potential implications for future therapies.
-
Pediatric Prehospital Airway Resuscitation for Critically Ill Children
This grant tests the best way for paramedics to manage breathing tubes and other airways in seriously ill children before they reach the hospital.
-
From Social Breakups to Brain Changes in Alzheimer’s and Related Dementias
This grant explores how losing social connections may trigger brain changes and inflammation linked to Alzheimer’s disease and related dementias.
-
Understanding why patients with blood cancers start and stick with oral cancer medicines
A study to learn what helps or hinders Black patients with blood cancers in starting and continuing their prescribed oral cancer medicines.
-
How sex and hormones affect alcohol's impact on sleep in adults
This study tests how sex and hormone changes influence how alcohol disrupts sleep in healthy adults, with a focus on women aged 21-45.
-
Natural products to block IL-8 signaling and prevent Barrett's Esophagus from turning into esophageal cancer
A搜索-friendly plan to use safe natural compounds to interrupt a key inflammatory signal (IL-8) and stop Barrett’s esophagus from turning into esophageal cancer in people with GERD.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.